Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31015899 | 0.88 | KDM4E (0.46) | KDM4EAHRALDH1A1MAPTHSD17B10 | |
| SCHEMBL25205148 | 0.88 | KDM4E (0.46) | KDM4EAHRALDH1A1MAPTHSD17B10 | |
| SCHEMBL20893409 | 0.87 | KDM4E (0.52) | KDM4EAHRALDH1A1MAPTHSD17B10 | |
| SCHEMBL18394631 | 0.85 | KDM4E (0.67) | KDM4EAHRALDH1A1MAPTHSD17B10 | |
| SCHEMBL2317088 | 0.82 | KDM4E (0.57) | KDM4EALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL6964091 | 0.80 | KDM4E (0.71) | KDM4EAHRALDH1A1MAPTHSD17B10 | |
| SCHEMBL20893375 | 0.79 | MAPT (0.62) | KDM4EAHRALDH1A1MAPTTSHR | |
| SCHEMBL30136795 | 0.79 | MAPT (0.62) | KDM4EAHRALDH1A1MAPTTSHR | |
| SCHEMBL14709428 | 0.79 | MEN1 (0.56) | KDM4EALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL13155390 | 0.78 | PTGS2 (0.47) | KDM4EAHRALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | KDM4E 4266/4885AHR 1926/4885ALDH1A1 1647/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | KDM4E 4275/4885AHR 1933/4885ALDH1A1 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.